Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity
In this report, we present a case study of how pharmacogenomics and pharmacometabolomics can be useful to characterize safety and pharmacokinetic profiles in early phase new drug development clinical trials. During conducting a first-in-human trial for a new molecular entity, we were able to determi...
Saved in:
| Main Authors: | Jaeseong Oh, Sojeong Yi, Namyi Gu, Dongseong Shin, Kyung-Sang Yu, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central
2018-09-01
|
| Series: | Genomics & Informatics |
| Subjects: | |
| Online Access: | http://genominfo.org/upload/pdf/gi-2018-16-3-52.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of depression in Brazil and the feasibility of incorporating pharmacogenomics as an auxiliary tool in antidepressant treatment
by: Rafaela Slaviero Pinheiro Cerdeira, et al.
Published: (2025-01-01) -
Exploring the preparedness of hospital pharmacists practising in Southwest London for implementing pharmacogenomics testing
by: Thuy Mason, et al.
Published: (2024-12-01) -
Pharmacometabolomics Enables Real-World Drug Metabolism Sciences
by: Fleur B. Nijdam, et al.
Published: (2025-01-01) -
Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine
by: Mi Seon Youn, et al.
Published: (2024-12-01) -
Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder
by: Chaoli Chen, et al.
Published: (2024-11-01)